Search Results - "Dent, Gersham"

Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis by Kanhai, Kawita M. S., Goulooze, Sebastiaan C., Grond, Jeroen, Harms, Amy C., Hankemeier, Thomas, Verma, Ajay, Dent, Gersham, Chavez, Juan, Meijering, Henri, Groeneveld, Geert Jan

“…The majority of disease modifying therapies for multiple sclerosis (MS) reduce inflammation, but do no’t target remyelination. Development of remyelinating…”
Get full text

Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge by Wolf, Daniel H., Satterthwaite, Theodore D., Loughead, James, Pinkham, Amy, Overton, Eve, Elliott, Mark A., Dent, Gersham W., Smith, Mark A., Gur, Ruben C., Gur, Raquel E.

“…Rationale Impaired emotion processing in schizophrenia predicts broader social dysfunction and has been related to negative symptom severity and amygdala…”
Get full text

Rapid Induction of Corticotropin-Releasing Hormone Gene Transcription in the Paraventricular Nucleus of the Developing Rat by Dent, Gersham W., Smith, Mark A., Levine, Seymour

“…Abstract Neonates from postnatal days (pnd) 4–14 display a minimal pituitary-adrenal response to mild stress, the so-called stress hyporesponsive period…”
Get full text

Brain corticotropin-releasing hormone (CRH) circuits in the developing rat: Effect of maternal deprivation by Vazquez, Delia M., Bailey, Charles, Dent, Gersham W., Okimoto, Darren K., Steffek, Amy, López, Juan F., Levine, Seymour

“…Early in life, there is a delicate and critical balance aimed to maintain low hormone responses derived from the stress responsive…”
Get full text

GABAergic circuits and the stress hyporesponsive period in the rat: Ontogeny of glutamic acid decarboxylase (GAD) 67 mRNA expression in limbic–hypothalamic stress pathways by Dent, Gersham, Choi, Dennis C, Herman, James P, Levine, Seymour

“…Abstract Development of the hypothalamo–pituitary–adrenocortical (HPA) axis is marked by a diminution in stress responsiveness early in the postnatal period…”
Get full text

Differential Expression of c-fos and Tyrosine Hydroxylase mRNA in the Adrenal Gland of the Infant Rat: Evidence for an Adrenal Hyporesponsive Period by Okimoto, Darren K, Blaus, Alison, Schmidt, Mathias, Gordon, M. Kathleen, Dent, Gersham W, Levine, Seymour

“…Rats exhibit a stress hyporesponsive period from postnatal day (PND) 4–14 in which the neonate displays a minimal corticosterone response to stress. We used…”
Get full text

Stress-induced alterations in corticotropin-releasing hormone and vasopressin gene expression in the paraventricular nucleus during ontogeny by Dent, G W, Okimoto, D K, Smith, M A, Levine, S

“…From postnatal day (PND) 4 to 14, neonates display a minimal pituitary-adrenal response to mild stress, the so-called 'stress hyporesponsive period' (SHRP)…”
Get more information

Maternal deprivation increases cell death in the infant rat brain by Zhang, Li-Xin, Levine, Seymour, Dent, Gersham, Zhan, Yutian, Xing, Guoqiang, Okimoto, Darren, Kathleen Gordon, M, Post, Robert M, Smith, Mark A

“…Prolonged separation from the mother can interfere with normal growth and development and is a significant risk factor for adult psychopathology. In rodents,…”
Get full text

Gene expression profiling in the amygdala: An approach to examine the molecular substrates of mammalian behavior by Dent, Gersham W, O'Dell, Dianne M, Eberwine, James H

“…The molecular substrates of behavior have been difficult to assess because of the large number of messenger RNAs (mRNAs) expressed in a given brain region, the…”
Get full text

Update to: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease by Rubel, C., Chen, T., Dent, Gersham

Get full text

CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab by Nisenbaum, Laura, Martone, Robert, Chen, Tianle, Rajagovindan, Rajasimhan, Dent, Gersham, Beaver, John, Rubel, Carrie, Racine, Annie, He, Ping, Harrison, Katie, Dean, Robert, Vandijck, Manu, Haeberlein, Samantha Budd

“…Introduction We assessed the use of cerebrospinal fluid (CSF) biomarkers as an alternative to positron emission tomography (PET) for brain amyloid beta (Aβ)…”
Get full text

Reductions in Biomarkers of Alzheimer’s Disease Pathophysiology Following Treatment With Aducanumab Were Associated With Slowing in Clinical Decline (P1-1.Virtual) by Chen, Tianle, Rajagovindan, Rajasimhan, Nisenbaum, Laura, Tian, Ying, Muralidharan, Kumar Kandadi, Dent, Gersham, He, Ping, Castrillo-Viguera, Carmen, Haeberlein, Samantha Budd

“…Abstract only…”
Get full text

Concordance of CSF biomarkers with amyloid PET at baseline in EMERGE/ENGAGE, phase 3 studies of aducanumab in patients with early Alzheimer’s disease by Rubel, Carrie E., Nisenbaum, Laura, Chen, Tianle, Dent, Gersham, Fraser, Kyle, Graham, Danielle, Harrison, Katie, He, Ping, Racine, Annie M, Rajagovindan, Raj, Beaver, John, Haeberlein, Samantha Budd

“…Background Recent technical performance improvements with the introduction of fully automated platforms have made cerebrospinal fluid (CSF) biomarkers…”
Get full text

Reductions in biomarkers of Alzheimer’s disease pathophysiology following treatment with aducanumab were associated with slowing in clinical decline by Rajagovindan, Raj, Chen, Tianle, Nisenbaum, Laura, Tian, Ying, Muralidharan, Kumar Kandadi, Dent, Gersham, He, Ping, Castrillo‐Viguera, Carmen, Haeberlein, Samantha Budd

“…Background Alzheimer’s disease (AD) is characterized by the accumulation of amyloid beta (Aβ) and tau in the brain. Aducanumab is a human monoclonal antibody…”
Get full text

Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial by Thornton, Charles A, Moxley, Richard Thomas, Eichinger, Katy, Heatwole, Chad, Mignon, Laurence, Arnold, W David, Ashizawa, Tetsuo, Day, John W, Dent, Gersham, Tanner, Matthew K, Duong, Tina, Greene, Ericka P, Herbelin, Laura, Johnson, Nicholas E, King, Wendy, Kissel, John T, Leung, Doris G, Lott, Donovan J, Norris, Daniel A, Pucillo, Evan M, Schell, Wendy, Statland, Jeffrey M, Stinson, Nikia, Subramony, Sub H, Xia, Shuting, Bishop, Kathie M, Bennett, C Frank

“…Myotonic dystrophy type 1 results from an RNA gain-of-function mutation, in which DM1 protein kinase (DMPK) transcripts carrying expanded trinucleotide repeats…”
Get full text

Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1 by Laforce, Robert Jr, Dallaire-Théroux, Caroline, Racine, Annie M., Dent, Gersham, Salinas-Valenzuela, Cristian, Poulin, Elizabeth, Cayer, Anne-Marie, Bédard-Tremblay, Daphnée, Rouleau-Bonenfant, Thierry, St-Onge, Frédéric, Schraen-Maschke, Susanna, Beauregard, Jean-Mathieu, Sergeant, Nicolas, Puymirat, Jack

“…Objective To investigate Tau pathology using multimodal biomarkers of neurodegeneration and neurocognition in participants with myotonic dystrophy type 1…”
Get full text

The acetylcholine release enhancer linopirdine induces Fos in neocortex of aged rats by DENT, Gersham W, RULE, Bonni L, YUTIAN ZHAN, GRZANNA, Reinhard

“…Centrally acting cholinergic agents induce the immediate early gene c-fos in the rat brain resulting in transient increases of Fos protein, most notably in the…”
Get full text

The ontogeny of the neuroendocrine response to endotoxin by Dent, Gersham W, Smith, Mark A, Levine, Seymour

“…During development, the hypothalamic–pituitary–adrenal (HPA) axis is normally hyporesponsive between postnatal days (pnd) 4 and 14. This interval has been…”
Get full text

Brief assessment of cognitive function in myotonic dystrophy: Multicenter longitudinal study using computer‐assisted evaluation by Deutsch, Gayle K., Hagerman, Katharine A., Sampson, Jacinda, Dent, Gersham, Dekdebrun, Jeanne, Parker, Dana M., Thornton, Charles A., Heatwole, Chad R., Subramony, Sub H., Mankodi, Ami K., Ashizawa, Tetsuo, Statland, Jeffrey M., Arnold, W. David, Moxley, Richard T., Day, John W.

“…Introduction/Aims Myotonic dystrophy type 1 (DM1) is known to affect cognitive function, but the best methods to assess central nervous system involvement in…”
Get full text

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease: Developments in clinical trials and cognitive assessment by Haeberlein, Samantha Budd, von Hehn, Christian, Tian, Ying, Chalkias, Spyros, Muralidharan, Kumar Kandadi, Chen, Tianle, Wu, Shuang, Skordos, LeAnne, Nisenbaum, Laura, Rajagovindan, Raj, Dent, Gersham, Harrison, Katie, Nestorov, Ivan, Zhu, Ying, Mallinckrodt, Craig, Sandrock, Alfred

“…Abstract Background Aducanumab is a human monoclonal antibody that selectively targets aggregated forms of Aβ, including soluble oligomers and insoluble…”
Get full text